Lymphoma Archives - Medical Conferences

Meet the Expert: Samantha Nier on the added value of patient advocacy –not just for patients

Expert

Samantha Nier, Acute Leukemia Advocates Network

1 August 2024 14:16

No cardioprotective effect of ACE inhibitors in patients with cancer

Presented By

Dr David Austin, South Tees Hospitals, UK

Trial

Phase 3, PROACT

Conference

ACC 2024

Type

Peer-reviewed article

16 May 2024 14:06

Is allogeneic stem cell transplantation a solid option in R/R LBCL or R/R T-cell lymphoma?

Presented By

Prof. Bertram Glass, Helios Klinikum Berlin-Buch, Germany

Trial

Phase 2, ASTRAL

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:00

Encouraging results for the addition of acalabrutinib to lenalidomide and rituximab in follicular lymphoma

Presented By

Dr Paolo Strati, MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 15:00

Can ibrutinib ameliorate outcomes in R/R ABC-DLBCL undergoing autoSCT?

Presented By

Dr Charalambos Andreadis, University of California San Francisco, USA

Trial

Phase 3, A051301/BMT-CTN 1201

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

Primary phase 2 efficacy and safety results of M-Pola in relapsed/refractory LBCL

Presented By

Dr Elizabeth Budde, City of Hope National Medical Center, CA, USA

Trial

Phase 1/2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

SYMPATICO: Ibrutinib plus venetoclax boosts PFS in R/R mantle cell lymphoma

Presented By

Prof. Michael Wang, University of Texas, TX, USA

Trial

Phase 3, SYMPATICO

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

Interview: Medicare’s first drug price negotiations: concerning?

Expert

Prof. Marc Bonaca, University of Colorado, USA

4 January 2024 15:06

How can we further improve lymphoma care?

Expert

Lorna Warwick, Lymphoma Coalition

14 September 2023 09:16

Radiotherapy or not in patients with PMBCL after immunochemotherapy?

Presented By

Dr Maurizio Martelli, University Sapienza Roma, Italy

Trial

IELSG37

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:16

Zandelisib promising in relapsed/refractory indolent B-cell NHL

Presented By

Dr Takahiro Kumode, Kindai University, Japan

Trial

Phase 2, MIRAGE

Conference

EHA 2023

Type

Peer-reviewed article

2 August 2023 16:05

Next-generation cell therapies for cancer: CAR-NK cells

Presented By

Dr Katy Rezvani, MD Anderson Cancer Center, TX, USA

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:20

Novel drugs and strategies around ASCT for Hodgkin lymphoma

Presented By

Dr Anna Sureda, Catalan Institute of Oncology, Spain

Conference

EBMT 2023

Type

Peer-reviewed article

15 June 2023 17:15

Statins associated with reduced heart dysfunction from anthracyclines

Presented By

Prof. Tomas Neilan, Massachusetts General Hospital, MA, USA

Trial

Phase 2, STOP-CA

Conference

ACC 2023

Type

Peer-reviewed article

7 June 2023 09:58

High-dose chemotherapy plus ASCT superior to standard immuno-chemotherapy in primary CNS lymphoma

Presented By

Prof. Gerald Illerhaus, Klinikum Stuttgart, Germany

Trial

Phase 3, MATRix/IELSG43

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:37

Odronextamab has considerable anti-tumour effects in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Presented By

Prof. Won-Seog Kim, Samsung Medical Center, South Korea

Trial

Phase 2, ELM-2 trial

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:30

Excellent results for AFM13-complexed NK cells in CD30-positive lymphoma

Presented By

Dr Yago Nieto, University of Texas, TX, USA

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:27

CAR-Hematotox score predicts toxicity, infections, and clinical outcomes in MCL

Presented By

Dr Kai Rejeski, LMU Munich, Germany

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 12:23

Novel first-line treatment option for mantle cell lymphoma

Presented By

Prof. Michael Wang, Anderson Cancer Center, TX, USA

Trial

Phase 3, SHINE

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:30

DA-EPOCH-R is equally effective but less toxic compared with CODOX-M/R-IVAX in high-risk Burkitt lymphoma

Presented By

Prof. Martine Chamuleau, Amsterdam UMC, the Netherlands

Trial

Phase 3, HOVON/SAKK

Conference

EHA 2022

Type

News article

1 July 2022 11:32

Most re-hospitalisations within first month from CAR T-cell infusion

Expert

Dr Kelly Kenzik, Institute for Cancer Outcomes and Survivorship, University of Alabama, USA

Conference

ASH 2021

Type

News article

4 February 2022 11:36

CD22-directed CAR T-cell therapy safe and well-tolerated in R/R LBCL

Expert

Dr Matthew J. Frank, Stanford University School of Medicine, USA

Conference

ASH 2021

Type

News article

4 February 2022 11:30

High rate of rapid and complete responses with axi-cel in high-risk large B-cell lymphoma

Expert

Dr Sattva S. Neelapu, MD Anderson Cancer Center, Houston, USA

Trial

ZUMA-12

Conference

ASH 2021

Type

News article

4 February 2022 11:25

Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL

Expert

Dr Grzegorz Nowakowski, Mayo Clinic, Rochester, USA

Trial

Cohort study, RE-MIND2

Conference

ASH 2021

Type

News article

4 February 2022 11:08

Liso-cel superior to standard-of-care as second-line therapy in large B-cell lymphoma

Expert

Dr Manali Kamdar, University of Colorado Cancer Center, Denver, USA

Trial

Phase 3, TRANSFORM

Conference

ASH 2021

Type

News article

4 February 2022 10:28

CIRS is predictive of outcomes in CAR T-cell recipients with R/R DLBCL

Expert

Dr Geoffrey Shouse, City of Hope Comprehensive Cancer Center, USA

Conference

ASH 2021

Type

News article

4 February 2022 10:20

Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma

Expert

Dr Frederick Locke, Moffitt Cancer Cancer, Tampa, Florida, USA

Trial

Phase 3, ZUMA-7

Conference

ASH 2021

Type

News article

4 February 2022 10:10

Comparable outcomes with second-line tisa-cel versus standard-of-care for relapsed/refractory aggressive NHL

Expert

Dr Michael R. Bishop, David and Etta Jonas Center for Cellular Therapy, University of Chicago, USA

Trial

Phase 3, BELINDA

Conference

ASH 2021

Type

News article

4 February 2022 10:03

Improved QoL with axi-cel versus standard-of-care in R/R LBCL

Expert

Dr Mahmoud Elsawy, Dalhousie University, Halifax, USA

Trial

Phase 3, ZUMA-7

Conference

ASH 2021

Type

News article

4 February 2022 09:48

Mutational analyses are predictive in malignant lymphomas

Presented By

Dr Ismael Fernández-Miranda, Institute of Sanitary Investigation Puerta de Hierro, Spain & Dr Shan-Shan Li, Hospital of Sun Yat-sen University, China

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:19

Low numbers of M2 macrophages in tumour microenvironment associated with superior response to immunotherapy in Hodgkin lymphoma

Presented By

Dr Liudmila Fedorova, Pavlov University, Russia

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:18

Escalating the ESCALADE trial: untreated diffuse large B-cell lymphoma

Presented By

Dr Laurie Sehn, University of British Columbia, Vancouver, Canada

Trial

Phase 3, ESCALADE

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 12:36

Immuno-oncology agents are effective in treating classic Hodgkin’s lymphoma

Presented By

Dr Marc André, Centre Hospitalier Universitaire UCL Namur, Belgium

Trial

CheckMate 205; KEYNOTE-087

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 12:26

MATRix with ASCT: best long-term survival for primary CNS lymphoma

Presented By

Dr Gerald Illerhaus, Klinikum der Landeshauptstadt Stuttgart, Germany

Trial

Phase 2, IELSG32

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 12:05

Naratuximab emtansine + rituximab safe and effective in diffuse large B-cell lymphoma

Presented By

Dr Moshe Yair Levy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, USA

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 11:55

The journey ahead for CAR T-cell therapy in r/r follicular lymphoma

Presented By

Dr Bastian von Tresckow, University Hospital Essen, Germany

Trial

ZUMA-5; ELARA

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 11:47

ZUMA-5 vs SCHOLAR-5: Axicabtagene ciloleucel significantly improves FL outcome

Presented By

Prof. John Gribben, Barts Cancer Institute, UK

Trial

ZUMA-5; SCHOLAR-5

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 11:18

Promising chemo-free treatment options in r/r DLBCL

Presented By

Prof. Marco Ladetto, University del Piemonte Orientale, Italy

Trial

LOTIS-2

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 11:17

CD58 aberrations limit durable responses to CD19 CAR T-cell therapy

Presented By

Dr Robbie Majzner, Stanford University, California, USA

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 10:15

More complicated course of COVID-19 in leukaemia patients

Presented By

Dr Susanne Ghandili, University Medical Center Hamburg-Eppendorf, Germany

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:34

PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma

Presented By

Dr Peter Borchmann, University Hospital of Cologne, Germany

Trial

Phase 3, HD17

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 12:51

Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma

Presented By

Prof. Pier Luigi Zinzani, University of Bologna, Italy

Trial

Phase 3, KEYNOTE-204

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 12:38

Promising first-in-human trial of epcoritamab in B-NHL

Presented By

Dr Martin Hutchings, Copenhagen University Hospital, Denmark

Trial

Phase 1/2, GEN3013

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 12:30

Venetoclax + navitoclax promising for R/R ALL or LL

Presented By

Prof. Elias Jabbour , University of Texas MS Anderson Cancer Centre, USA

Trial

Phase 1

Conference

EHA 2020

Type

Peer-reviewed article

28 August 2020 12:23

Nivolumab/brentuximab vedotin in R/R HL: good CMR rates

Presented By

Prof. Christine Mauz-Körholz, Justus-Liebig-Universität Gießen, Germany

Trial

Phase 2, Checkmate 744

Conference

EHA 2020

Type

Peer-reviewed article

28 August 2020 12:09

Mosunetuzumab: complete remissions in non-Hodgkin lymphoma

Presented By

Prof. Stephen Schuster, University of Pennsylvania, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 09:50

Off-the-shelf natural killer cells

Presented By

Dr Jode Goodridge, Fate Therapeutics, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 09:38

Brentuximab vedotin continues to demonstrate superior clinical activity in classical Hodgkin lymphoma

Presented By

Dr Steven Horwitz , Memorial Sloan Kettering Cancer Center, USA

Trial

Phase 3, ECHELON-1

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 20:49

Infectious complications mild and not common in patients receiving CAR-T therapy for diffuse large B cell lymphoma

Presented By

Dr Roberta Di Blasi, Hospital Saint-Louis, France

Trial

JULIET and ZUMA1

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 19:55

Obinutuzumab/polatuzumab in follicular lymphoma

Presented By

Prof. Wojciech Jurczak, Jagiellonian University, Poland

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 17:13

Psoriasis and Biologics: The Beat Goes On

Presented By

Prof. Mark Lebwohl, Mount Sinai School of Medicine, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 14:06